Artificial intelligence is entering pharmaceutical manufacturing at an unprecedented pace.
From predictive maintenance to batch monitoring to automated decision-making, the potential is enormous.
Efficiency improves.
Insights deepen.
Processes become more adaptive.
But alongside that opportunity comes a fundamental question:
Are we moving faster than our ability to control what we are implementing?
In regulated environments, innovation is not just about capability.
It is about control.
AI systems introduce new challenges:
- How do you validate a model that evolves over time?
- How do you ensure decisions are explainable?
- How do you maintain data integrity across complex systems?
Traditional validation approaches were not designed for adaptive technologies.
They assume stability.
They assume predictability.
AI challenges both.
And yet, the expectation from regulators has not changed.
Systems must be controlled.
Data must be reliable.
Decisions must be justified.
The risk is not AI itself.
The risk is implementing it without a framework that ensures those expectations are met.
Organizations that succeed in this space will not be the ones that move fastest.
They will be the ones that move deliberately.
They will define boundaries.
They will establish governance.
They will ensure that every output can be trusted—and explained.
Because in GMP environments, innovation is only valuable if it is compliant.
Otherwise, it is just risk—scaled.
Christine Feaster
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
